Trial Profile

ANGIO-A: Safety and Tolerability of Oral Cyclophosphamide and Sorafenib With Intravenous Bevacizumab With the Addition of Atezolizumab in Pediatric Solid Tumor Patients

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 18 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Cyclophosphamide (Primary) ; Sorafenib (Primary)
Indications Liver cancer; Solid tumours
Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
Acronyms ANGIO-A

18 Feb 2026 Status changed from suspended to recruiting.
25 May 2025 Status changed from recruiting to suspended. (Temporary closure due to review of toxicity )
29 Mar 2024 Results determining if SOR systemic exposure can be targeted to an AUC by day 21 of course 1 in 60 percent of patients when given in combination with CTX, BEV, and ATZ, presented at the 125th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com